Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Bifidobacterium infantis 35624 is a clinically studied probiotic strain that modulates gut microbiota through production of short-chain fatty acids and antimicrobial compounds. This strain specifically reduces inflammatory cytokines and enhances intestinal barrier function to improve digestive health and IBS symptoms.
Reported Benefits (Provisional)
Origin & History
Bifidobacterium infantis 35624 is a specific strain of probiotic bacteria isolated from the human gastrointestinal tract. It is cultivated under controlled conditions to ensure purity and efficacy. This strain is often used in supplements for its gut health benefits.
Research Narrative (Provisional)
Several randomized controlled trials (RCTs) have demonstrated the efficacy of Bifidobacterium infantis 35624 in managing IBS symptoms. Meta-analyses support its role in enhancing gut health and immune function.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Contains live beneficial bacteria. - Supports production of short-chain fatty acids. - Contributes to maintaining a healthy gut flora balance.
Reported Mechanism (Provisional)
B. infantis 35624 produces acetate, propionate, and butyrate short-chain fatty acids that strengthen tight junctions in the intestinal epithelium and reduce pro-inflammatory cytokines IL-6 and TNF-α. The strain synthesizes bacteriocins that inhibit pathogenic bacteria while stimulating regulatory T-cells through Toll-like receptor 2 signaling. It also increases secretory IgA production and enhances mucin secretion by goblet cells.
Clinical Narrative (Provisional)
Multiple randomized controlled trials with 362 IBS patients demonstrated 50% reduction in abdominal pain, bloating, and bowel movement difficulty over 4-8 weeks. A placebo-controlled study of 75 participants showed significant improvements in inflammatory markers including reduced IL-10 and increased anti-inflammatory cytokines. Clinical evidence is robust with consistent outcomes across studies, though most trials were conducted on adults with IBS rather than broader populations.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.